Gout and the risk of Alzheimer's disease: A population-based, BMI-matched cohort study

Annals of the Rheumatic Diseases

Volumn 75, Issue 3, 2016, Pages 547-551

  Lu, Na ^a,b   Dubreuil, Maureen ^a   Zhang, Yuqing ^a   Neogi, Tuhina ^a   Rai, Sharan K ^c   Ascherio, Alberto ^d   Hernán, Miguel A ^d   Choi, Hyon K ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GOUT; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROPROTECTION; OSTEOARTHRITIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOCIAL ISOLATION; COMORBIDITY; FACTUAL DATABASE; HYPERURICEMIA; INCIDENCE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODEL; PROTECTION; UNITED KINGDOM;

AGED; ALZHEIMER DISEASE; BODY MASS INDEX; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; GOUT; HUMANS; HYPERURICEMIA; INCIDENCE; MALE; MIDDLE AGED; OBESITY; OSTEOARTHRITIS; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RISK FACTORS; UNITED KINGDOM;

EID: 84960086751     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206917     Document Type: Article

References (41)

1. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125:679-687 e1.
2. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42.
3. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
4. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10.
5. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
6. Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 1993;84:407-12.
7. Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-7.
8. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716-23.
9. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-8.
10. Schwarzschild MA, Ascherio A, Beal MF, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141-50.
11. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-9.
12. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65:631-41.
13. Euser SM, Hofman A, Westendorp RG, et al. Serum uric acid and cognitive function and dementia. Brain 2009;132:377-82.
14. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7.
15. National-Health-Service(NHS). Read Codes-NHS Connecting for Health.
16. FirstDataBank. Drug Databases-Multilex Drug Data File.
17. Choi HK, Curhan G. Coffee consumption and risk of incident gout in women: the Nurses' Health Study. Am J Clin Nutr 2010;92:922-7.
18. Gustafson DR, Backman K, Joas E, et al. 37 years of body mass index and dementia: observations from the prospective population study of women in Gothenburg, Sweden. J Alzheimers Dis 2012;28:163-71.
19. Tolppanen AM, Ngandu T, Kareholt I, et al. Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. J Alzheimers Dis 2014;38:201-9.
20. Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:d8190.
21. Alonso A, Rodriguez LA, Logroscino G, et al. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696-700.
22. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175-8.
23. Dunn N, Mullee M, Perry VH, et al. Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis Assoc Disord 2005;19:91-4.
24. Imfeld P, Brauchli Pernus YB, Jick SS, et al. Epidemiology, co-morbidities, and medication use of patients with Alzheimer's disease or vascular dementia in the UK. J Alzheimers Dis 2013;35:565-73.
25. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111-28.
26. Morris R, Carstairs V. Which deprivation? A comparison of selected deprivation indexes. J Public Health Med 1991;13:318-26.
27. Townsend P, Phillimore P, Beattie A. Health and deprivation : inequality and the North. London; New York: Croom Helm, 1988.
28. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
29. Raghunathan TE, Lepkowski JM, Van Hoewyk J, et al. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodology 2001;27:85-95.
30. Dubreuil M, Rho YH, Zhu Y, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 2013.
31. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-62.
32. Rundles RW, Wyngaarden JB. Drugs and uric acid. Annu Rev Pharmacol 1969;9:345-62.
33. Davies KJ, Sevanian A, Muakkassah-Kelly SF, et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 1986;235:747-54.
34. Yu ZF, Bruce-Keller AJ, Goodman Y, et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613-25.
35. Everse J, Coates PW. The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds. Free Radic Biol Med 2004;37:839-49.
36. Anderson RF, Harris TA. Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson's disease. Free Radic Res 2003;37:1131-6.
37. Cipriani S, Desjardins CA, Burdett TC, et al. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS ONE 2012;7:e37331.
38. Gong L, Zhang QL, Zhang N, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3beta signaling pathway. J Neurochem 2012;123:876-85.
39. Chen X, Burdett TC, Desjardins CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013;110:300-5.
40. Hooper DC, Bagasra O, Marini JC, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 1997;94:2528-33.
41. Waugh WH. Inhibition of iron-catalyzed oxidations by attainable uric acid and ascorbic acid levels: therapeutic implications for Alzheimer's disease and late cognitive impairment. Gerontology 2008;54:238-43.